SG11202109982YA - Drug and method for treating or preventing diabetes complications using same drug - Google Patents

Drug and method for treating or preventing diabetes complications using same drug

Info

Publication number
SG11202109982YA
SG11202109982YA SG11202109982YA SG11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA SG 11202109982Y A SG11202109982Y A SG 11202109982YA
Authority
SG
Singapore
Prior art keywords
drug
treating
preventing diabetes
diabetes complications
same
Prior art date
Application number
Other languages
English (en)
Inventor
Keita Shibata
Ryosuke Shinouchi
Terumasa Hashimoto
Koji Nobe
Original Assignee
Univ Showa
Tms Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Showa, Tms Co Ltd filed Critical Univ Showa
Publication of SG11202109982YA publication Critical patent/SG11202109982YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202109982Y 2019-03-12 2020-03-12 Drug and method for treating or preventing diabetes complications using same drug SG11202109982YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (1)

Publication Number Publication Date
SG11202109982YA true SG11202109982YA (en) 2021-10-28

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109982Y SG11202109982YA (en) 2019-03-12 2020-03-12 Drug and method for treating or preventing diabetes complications using same drug

Country Status (15)

Country Link
US (1) US20220218664A1 (enrdf_load_stackoverflow)
EP (1) EP3939659A4 (enrdf_load_stackoverflow)
JP (1) JPWO2020184691A1 (enrdf_load_stackoverflow)
KR (1) KR20220009371A (enrdf_load_stackoverflow)
CN (1) CN114126711A (enrdf_load_stackoverflow)
AU (1) AU2020238177A1 (enrdf_load_stackoverflow)
BR (1) BR112021018084A8 (enrdf_load_stackoverflow)
CA (1) CA3133204A1 (enrdf_load_stackoverflow)
CL (1) CL2021002373A1 (enrdf_load_stackoverflow)
EA (1) EA202192483A1 (enrdf_load_stackoverflow)
IL (1) IL286289A (enrdf_load_stackoverflow)
MX (1) MX2021011007A (enrdf_load_stackoverflow)
PE (1) PE20220333A1 (enrdf_load_stackoverflow)
SG (1) SG11202109982YA (enrdf_load_stackoverflow)
WO (1) WO2020184691A1 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
EP4293028A4 (en) * 2021-02-10 2024-10-30 Shanghai Senhui Medicine Co., Ltd. Smtp-7 derivative and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ｎｇｆ作用増強因子
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
EP1944027A4 (en) 2005-10-06 2009-08-19 Univ Tokyo Nat Univ Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD OF MANUFACTURE THEREOF
JP4395540B2 (ja) 2006-03-27 2010-01-13 農工大ティー・エル・オー株式会社 トリプレニルフェノール化合物及びトリプレニルフェノール化合物の製造方法並びに、血栓溶解促進剤
WO2010110026A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物
EP2452679B1 (en) * 2009-07-06 2014-05-28 National University Corporation Tokyo University Of Agriculture and Technology Triprenylphenolic cytoprotective agent
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
WO2012115209A1 (ja) * 2011-02-24 2012-08-30 国立大学法人東京農工大学 可溶性エポキシドハイドロラーゼ阻害剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Also Published As

Publication number Publication date
JPWO2020184691A1 (enrdf_load_stackoverflow) 2020-09-17
EP3939659A4 (en) 2022-12-21
US20220218664A1 (en) 2022-07-14
WO2020184691A1 (ja) 2020-09-17
KR20220009371A (ko) 2022-01-24
AU2020238177A1 (en) 2021-11-04
EA202192483A1 (ru) 2021-12-24
IL286289A (en) 2021-10-31
EP3939659A1 (en) 2022-01-19
BR112021018084A8 (pt) 2022-10-04
CA3133204A1 (en) 2020-09-17
CL2021002373A1 (es) 2022-06-17
PE20220333A1 (es) 2022-03-14
BR112021018084A2 (enrdf_load_stackoverflow) 2021-12-21
MX2021011007A (es) 2022-03-11
CN114126711A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
SG11202013239RA (en) Composition and method for treating pain
EP3766431A4 (en) MEDICAL DEVICE AND METHOD OF TREATMENT
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for the treatment or prevention of a C5-related disease
EP4043559A4 (en) IMPROVED URICASE AND METHODS OF TREATING HYPERURICAEMIA USING THE SAME
EP4158645A4 (en) DIGITAL DEVICE AND APPLICATION FOR MYOPIA TREATMENT
EP3609522A4 (en) METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES
EP3636281C0 (en) METHOD FOR TREATING DEPRESSION AND PHARMACEUTICAL COMPOSITION
IL284565A (en) A system for administering avalopertide transdermally and a method of use
SG11202109982YA (en) Drug and method for treating or preventing diabetes complications using same drug
EP3804759A4 (en) METHOD OF TREATING AND/OR PREVENTING REGNASE-1 RELATED DISEASES
EP3773546A4 (en) METHOD FOR TREATING POSTPRANDIAL HYPOGLYCAEMIA
EP3236961A4 (en) Pharmaceutical composition for preventing or treating cancer and method using thereof
EP3770949A4 (en) Treatment solution and treatment method
EP3677267A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
EP3579791A4 (en) BANDAGE FOR TREATMENT OF AMPUTE AND RELATED PROCEDURE
IL285828A (en) Compounds for the treatment and prevention of complications associated with extracellular neutrophil traps
IL286121A (en) Apparatus and method for tissue treatment
ZA202105143B (en) Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
EP4082577A4 (en) CANCER TREATMENT METHOD AND DRUG
EP3995147A4 (en) SUBSTANCE AND METHOD FOR THE TREATMENT OF A TUMOR
EP3746179A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF DIABETES
HK40089232A (en) Composition and method for treatment of diabetes
EP3852743A4 (en) PYRAZOLYLACYLPYRAZOLINE COMPOUNDS AND PAIN TREATMENT METHOD
AU2019904917A0 (en) Inhibitors and Methods for Treating Drug Addiction